Skip to content

Ovarian Cancer Research

Cancer ResearchsiRNA screen to identify modifiers of MCPH1 induced premature chromosome condensation

Following surgery for breast and ovarian cancer, many women have chemotherapy to reduce the chance of it recurring. Unfortunately, 30-40% of these patients have cancer cells that are resistant to current drugs. Dr Bell and her team have found that this is linked to the loss of a particular protein, MCPH1. By studying the killing of cells without MCPH1, they aim to progress the development of new drugs for women who are resistant to current chemotherapies.


  • Principal investigator: Dr Sandra Bell, Dr Jacquelyn Bond and Dr Ewan Morrison
  • Leeds Institute of Molecular Medicine, University of Leeds
  • Award amount: £156,551
  • Jan 2011 – October 2014



Cancer ResearchePRIME Yorkshire: electronic Patient self-Reported outcomes to Improve cancer Management and patient Experiences

As cancer survival rates improve, more people are living with and beyond cancer. Although many may be cured or in remission, they need follow up to detect recurrence and monitor after-effects of treatment, whilst those with advanced cancer need close monitoring. This project will build upon an existing electronic patient portal which allows patients to report symptoms and adverse effects of treatment, can provide appropriate advice, and alert clinicians to serious symptoms. By extending use of the system across Yorkshire the team aim to improve patient care, experiences and safety.


  • Principal investigator: Professor Galina Velikova
  • Leeds Institute of Cancer and Pathology
  • Award amount: £497,534
  • February 2016 – January 2020